Vistakon
VISTAKON®, division of Johnson & Johnson Vision Care, Inc., today announced that ACUVUE® OASYS™ Brand Contact Lenses with HYDRACLEAR® PLUS is now available in a plano lens for therapeutic use (8.4 mm base curve), and will be promoted to eye care professionals by the VISTAKON® Pharmaceuticals, LLC sales force.
The U.S. Food & Drug Administration granted an additional indication for ACUVUE® OASYS™ in October, 2007, approving the lens for therapeutic use as a bandage lens for certain acute and chronic ocular conditions. ACUVUE® OASYS™ for therapeutic use can also provide vision correction during healing if required.
FDA approval of ACUVUE® OASYS™ for therapeutic use as a bandage lens includes the following acute and chronic ocular conditions:
- For corneal protection in lid and corneal abnormalities such as entropion, trichiasis, tarsal scars and recurrent corneal erosion. In addition, it is indicated for protection where sutures or ocular structure malformation, degeneration or paralysis may result in the need to protect the cornea from exposure or repeated irritation.
- For corneal pain relief in conditions such as bullous keratopathy, epithelial erosion and abrasion, filamentary keratitis, post-keratoplasty.
- For use as a barrier during the healing process of epithelial defects such as chronic epithelial defects, corneal ulcer, neurotrophic and neuroparalytic keratitis, and chemical burns.
- For post surgical conditions where bandage lens use is indicated such as post refractive surgery, lamellar grafts, corneal flaps, and additional ocular surgical conditions
- For structural stability and protection in piggy back lens fitting where the cornea and associated surfaces are too irregular to allow for corneal rigid gas permeable lenses to be fit. In addition, the use of the lens can prevent irritation and abrasions in conditions where there are elevation differences in the host/graph junction or scar tissue.
ACUVUE® OASYS™ PLANO/2
ACUVUE® OASYSTM Brand Contact lenses are also indicated for daily wear vision correction and may also be worn for up to 6 consecutive nights/7 days of extended wear as recommended by an eye care professional. ACUVUE® OASYS™ can be worn continuously for up to six nights and seven days when used as a therapeutic lens. Contact lenses should not be worn for longer periods than recommended by an eye care professional. As with all contact lenses, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. When intended for vision correction, lenses should not be prescribed if patients have any eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. Consult the package insert for complete information. Complete information is also available from VISTAKON® by calling 1-800-843-2020 or by visiting www.ecp.acuvue.com.
Johnson & Johnson Vision Care Inc.
The VISTAKON® division of Johnson & Johnson Vision Care, Inc. specializes in disposable contact lenses which it markets under such brand names as ACUVUE®, ACUVUE® ADVANCE® with HYDRACLEAR® , ACUVUE® ADVANCE® for ASTIGMATISM, ACUVUE® OASYS™ with HYDRACLEAR® PLUS, ACUVUE® and ACUVUE® 2; 1-DAY ACUVUE® ;ACUVUE® BIFOCAL ; ACUVUE® TORIC, and ACUVUE® 2 COLOURSTM.
VISTAKON® Pharmaceuticals, LLC, specializes in the sales and marketing of ophthalmic pharmaceuticals. Headquartered in Jacksonville, Florida, the company markets four prescription ophthalmic agents: ALAMAST® (pemirolast potassium ophthalmic solution) 0.1%, BETIMOL® (timolol ophthalmic solution) 0.25% and .5%, IQUIX® (levofloxacin ophthalmic solution) 1.5%, and QUIXIN® (levofloxacin ophthalmic solution) 0.5% through a co-marketing agreement with Santen Incorporated.
# # #